Last reviewed · How we verify
Glucagon Nasal Powder [Baqsimi] — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Glucagon Nasal Powder [Baqsimi] (Glucagon Nasal Powder [Baqsimi]) — Eli Lilly and Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Glucagon Nasal Powder [Baqsimi] TARGET | Glucagon Nasal Powder [Baqsimi] | Eli Lilly and Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Glucagon Nasal Powder [Baqsimi] CI watch — RSS
- Glucagon Nasal Powder [Baqsimi] CI watch — Atom
- Glucagon Nasal Powder [Baqsimi] CI watch — JSON
- Glucagon Nasal Powder [Baqsimi] alone — RSS
Cite this brief
Drug Landscape (2026). Glucagon Nasal Powder [Baqsimi] — Competitive Intelligence Brief. https://druglandscape.com/ci/glucagon-nasal-powder-baqsimi. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab